MOUNTAIN VIEW, Calif., April 12 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced the release of Drug Model Explorer(TM) Web Server (DMX(R)) version 1.5. The new release will support increased compatibility with customer requirements for deployment of web applications and will allow future DMX releases to take advantage of .NET technologies.
DMX is a web-based tool that allows clinical drug development teams to present and exchange complex information on modeled drug attributes, and to efficiently compare probable outcomes based on different treatment strategies, patient populations and competing products.
DMX will continue to support Microsoft(R) SQL Server, a leading database product, and Oracle(R), the preferred database system in the pharmaceutical industry. DMX will also continue to process simulations created in SAS(R) XPORT transport format, a data exchange mechanism accepted by the Food and Drug Administration (FDA), as well as S-PLUS(R), a leading analysis software product.
“We continue to work closely with our customers to meet their changing and emerging technology needs,” said Shawn M. O’Connor, President and Chief Executive Officer. “Enhancement of the DMX architecture using .NET technologies responds to our customers’ drug development technology infrastructures and deployment requirements for enterprise web applications. In addition, enhancement of the DMX architecture will allow ongoing development activities to take advantage of component technologies for improved speed, security and integration with third party software. We believe we are illustrating our commitment to being responsive to our customers and to remaining at the forefront of technology development.”
About DMX
DMX allows clinicians, biostatisticians, marketers, and other members of clinical development teams to quickly visualize the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies. Pharsight believes that DMX will help increase the usage of quantitative-based decision-making in the drug development process. DMX can enhance the entire development team’s understanding of a drug’s likely clinical potential and limitations, and enable more efficient decision-making by providing direct interaction with modeling results presented as a series of intuitive plots and tables.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Safe Harbor
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the anticipated development and performance of Pharsight’s products and the expected benefits to customers from the use of Pharsight’s products. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in the demand for Pharsight’s products and services, changes in Pharsight’s research and development focus or operating strategies, the failure to develop new products and services or to keep pace with technological changes, delays in the release of new products and services, the failure of Pharsight’s products and services to obtain anticipated levels of customer acceptance or to meet customers’ expectations, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on February 13, 2006. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
NOTE: Pharsight, DMX, and Drug Model Explorer are registered trademarks or trademarks of Pharsight Corporation.
All other brand and product names are trademarks or registered trademarks of their respective holders.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, or Jennifer Beugelmans,+1-415-896-6820, or media, Steve DiMattia, +1-917-620-0590, all of EVCGroup, for Pharsight
Web site: http://www.pharsight.com//
